172 related articles for article (PubMed ID: 9605422)
1. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides.
Kirkpatrick DL; Kuperus M; Dowdeswell M; Potier N; Donald LJ; Kunkel M; Berggren M; Angulo M; Powis G
Biochem Pharmacol; 1998 Apr; 55(7):987-94. PubMed ID: 9605422
[TBL] [Abstract][Full Text] [Related]
2. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues.
Oblong JE; Chantler EL; Gallegos A; Kirkpatrick DL; Chen T; Marshall N; Powis G
Cancer Chemother Pharmacol; 1994; 34(5):434-8. PubMed ID: 8070012
[TBL] [Abstract][Full Text] [Related]
3. Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
Kirkpatrick DL; Watson S; Kunkel M; Fletcher S; Ulhaq S; Powis G
Anticancer Drug Des; 1999 Oct; 14(5):421-32. PubMed ID: 10766297
[TBL] [Abstract][Full Text] [Related]
4. Redox active disulfides: the thioredoxin system as a drug target.
Kirkpatrick DL; Ehrmantraut G; Stettner S; Kunkel M; Powis G
Oncol Res; 1997; 9(6-7):351-6. PubMed ID: 9406241
[TBL] [Abstract][Full Text] [Related]
5. A stable mixed disulfide between thioredoxin reductase and its substrate, thioredoxin: preparation and characterization.
Wang PF; Veine DM; Ahn SH; Williams CH
Biochemistry; 1996 Apr; 35(15):4812-9. PubMed ID: 8664271
[TBL] [Abstract][Full Text] [Related]
6. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione.
Ren X; Björnstedt M; Shen B; Ericson ML; Holmgren A
Biochemistry; 1993 Sep; 32(37):9701-8. PubMed ID: 8373774
[TBL] [Abstract][Full Text] [Related]
7. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress.
Smart DK; Ortiz KL; Mattson D; Bradbury CM; Bisht KS; Sieck LK; Brechbiel MW; Gius D
Cancer Res; 2004 Sep; 64(18):6716-24. PubMed ID: 15374989
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the thioredoxin system by PX-12 (1-methylpropyl 2-imidazolyl disulfide) impedes HIV-1 infection in TZM-bl cells.
Lundberg M; Mattsson Å; Reiser K; Holmgren A; Curbo S
Sci Rep; 2019 Apr; 9(1):5656. PubMed ID: 30948772
[TBL] [Abstract][Full Text] [Related]
9. Thioredoxin redox control of cell growth and death and the effects of inhibitors.
Powis G; Kirkpatrick DL; Angulo M; Baker A
Chem Biol Interact; 1998 Apr; 111-112():23-34. PubMed ID: 9679540
[TBL] [Abstract][Full Text] [Related]
10. Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1.
Vogt A; Tamura K; Watson S; Lazo JS
J Pharmacol Exp Ther; 2000 Sep; 294(3):1070-5. PubMed ID: 10945861
[TBL] [Abstract][Full Text] [Related]
11. The thioredoxin/thioredoxin reductase redox system and control of cell growth.
Powis G; Oblong JE; Gasdaska PY; Berggren M; Hill SR; Kirkpatrick DL
Oncol Res; 1994; 6(10-11):539-44. PubMed ID: 7620223
[TBL] [Abstract][Full Text] [Related]
12. Human IgG is substrate for the thioredoxin system: differential cleavage pattern of interchain disulfide bridges in IgG subclasses.
Magnusson CG; Björnstedt M; Holmgren A
Mol Immunol; 1997 Jul; 34(10):709-17. PubMed ID: 9430198
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer.
Weichsel A; Gasdaska JR; Powis G; Montfort WR
Structure; 1996 Jun; 4(6):735-51. PubMed ID: 8805557
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide and sorafenib in liver cancer cells.
Cao LP; Zhang C; Weng XY; Xie HY; Wu J; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):295-298. PubMed ID: 32247719
[No Abstract] [Full Text] [Related]
15. General acid/base catalysis in the active site of Escherichia coli thioredoxin.
Chivers PT; Raines RT
Biochemistry; 1997 Dec; 36(50):15810-6. PubMed ID: 9398311
[TBL] [Abstract][Full Text] [Related]
16. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of thioredoxin reductase (E.C. 1.6.4.5.) by antitumor quinones.
Mau BL; Powis G
Free Radic Res Commun; 1990; 8(4-6):365-72. PubMed ID: 2162313
[TBL] [Abstract][Full Text] [Related]
18. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
Baker AF; Dragovich T; Tate WR; Ramanathan RK; Roe D; Hsu CH; Kirkpatrick DL; Powis G
J Lab Clin Med; 2006 Feb; 147(2):83-90. PubMed ID: 16459166
[TBL] [Abstract][Full Text] [Related]
19. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
Kunkel MW; Kirkpatrick DL; Johnson JI; Powis G
Anticancer Drug Des; 1997 Dec; 12(8):659-70. PubMed ID: 9448705
[TBL] [Abstract][Full Text] [Related]
20. Glutathione- and thioredoxin-related enzymes are modulated by sulfur-containing chemopreventive agents.
Hu Y; Urig S; Koncarevic S; Wu X; Fischer M; Rahlfs S; Mersch-Sundermann V; Becker K
Biol Chem; 2007 Oct; 388(10):1069-81. PubMed ID: 17937621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
